Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tafasitamab

tafasitamab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tafasitamab

4 trials tracked of tafasitamab: 1 in phase 3 or 4.

4Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 2 Phase 1 1
  1. Phase 3 A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed
  2. Phase 2 Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL Completed
  3. Phase 2 Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi Completed
  4. Phase 1 Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
Oncology Meta-analysis
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Apr 16, 2026
Phase 1b trial finds tafasitamab combinations manageable in Japanese B-cell NHL patients
Hematology Phase I
Phase 1b trial finds tafasitamab combinations manageable in Japanese B-cell NHL patients Early study tests tafasitamab alone and in combinations for Japanese lymphoma patients
A phase 1b trial in 24 Japanese patients with relapsed/refractory or untreated B-cell NHL assessed tafasitamab alone or in combination.
Japanese lymphoma patients received new drug tafasitamab alone or with others, showing manageable side effects like low blood counts and nau…
Apr 3, 2026